Quintiles Transnational Holdings Inc  

(Public, NYSE:Q)   Watch this stock  
Find more results for Michael A. Cote´┐Ż
-2.03 (-3.41%)
Feb 5 - Close
NYSE real-time data - Disclaimer
Currency in USD
Range 56.80 - 59.53
52 week 56.66 - 80.45
Open 59.53
Vol / Avg. 1.77M/921,758.00
Mkt cap 7.36B
P/E 19.66
Div/yield     -
EPS 2.92
Shares 123.09M
Beta     -
Inst. own 90%
Feb 11, 2016
Q4 2015 Quintiles Transnational Holdings Inc Earnings Release - 9:30AM EST - Add to calendar
Feb 11, 2016
Q4 2015 Quintiles Transnational Holdings Inc Earnings Call - 8:00AM EST - Add to calendar
Jan 12, 2016
Quintiles Transnational Holdings Inc at JPMorgan Healthcare Conference
Nov 10, 2015
Quintiles Transnational Holdings Inc at Credit Suisse Healthcare Conference
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '15) 2014
Net profit margin 7.26% 6.45%
Operating margin 11.72% 10.81%
EBITD margin - 13.19%
Return on average assets 11.25% 11.07%
Return on average equity - -
Employees 32,600 -
CDP Score - -


4820 Emperor Blvd
DURHAM, NC 27703-8426
United States - Map
+1-919-9982000 (Phone)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Quintiles Transnational Holdings Inc. is a biopharmaceutical services company. The Company is a provider of biopharmaceutical development services and commercial outsourcing services. The Company is engaged in the development and commercialization of pharmaceutical therapies. It also offers therapeutic, scientific and analytical services to its biopharmaceutical and other healthcare customers. The Company offers its services through two segments: Product Development and Integrated Healthcare Services. Its product development segment is a contract research organization (CRO) and is focused on Phase II-IV clinical trials and associated laboratory and analytical activities. Its Integrated Healthcare Services segment provides services, including commercial services, such as contract pharmaceutical sales forces, and healthcare business services, such as phase research, market access and consulting, and health information analytics and technology consulting.

Officers and directors

Dennis B. Gillings CBE, Ph.D. Director
Age: 70
Bio & Compensation  - Reuters
Thomas H. Pike Chief Executive Officer, Director
Age: 55
Bio & Compensation  - Reuters
Michael R. McDonnell Chief Financial Officer, Executive Vice President
Age: 51
Bio & Compensation  - Reuters
Kevin K. Gordon Chief Operating Officer
Age: 52
Bio & Compensation  - Reuters
James H. Erlinger III Executive Vice President, General Counsel, Secretary
Age: 56
Bio & Compensation  - Reuters
John P. Connaughton Director
Age: 49
Bio & Compensation  - Reuters
Jonathan J. Coslet Director
Age: 50
Bio & Compensation  - Reuters
Hai-yuan Lo Director
Bio & Compensation  - Reuters
Michael J. Evanisko Independent Director
Age: 65
Bio & Compensation  - Reuters
Jack M. Greenberg CPA Chairman of the Board
Age: 72
Bio & Compensation  - Reuters